Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion

SKYE COMPLETES DOSING OF FINAL COHORT OF HEALTHY VOLUNTEERS IN STUDY OF…